Guanfacine Extended Release

The Formulary Management Expert Committee (FMEC) recommends that guanfacine extended release (XR) be reimbursed for the adjunct therapy to psychostimulants for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents, aged 6 years to 17 years, whose disease has responded suboptimally to psychostimulants, provided certain conditions are met. Guanfacine XR may be reimbursed for the adjunct therapy to psychostimulants for the treatment of ADHD in children and adolescents, aged 6 years to 17 years, whose disease has responded suboptimally to psychostimulants. Guanfacine XR should be discontinued if there are unacceptable toxicities. Guanfacine XR must represent good value to the drug plans.